阿立哌唑与奥氮平治疗首发精神分裂症对照研究

A control study of aripiprazole vs olanzapine in first-episode schizophrenia

目的探讨阿立哌唑治疗首发精神分裂症的临床疗效和安全性。方法将60例首发精神分裂症患者随机分为两组，每组30例，研究组口服阿立哌唑治疗，对照组口服奥氮平治疗，观察8周。于治疗前及治疗2周、4周、6周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（P〈0．01），治疗8周末，研究组显效率66．7％、有效率83．3％，对照组分别为70．0％、86．7％，两组比较差异无显著性（χ2=0．08、0．13，P〉0．05）。研究组不良反应发生率为33．3％，对照组为63．3％，研究组显著低于对照组（χ2=5．41，P〈0．05）。结论阿立哌唑能有效改善首发精神分裂症患者的各种精神症状，疗效显著且与奥氮平相当，不良反应轻微，对体质量几乎无影响，安全性高，依从性好。

Objective To explore the efficacy and safety of aripiprazole in first-episode schizophrenia. Methods Sixty first-episode schizophrenics were randomly assigned to two groups of 30 patients each, research group took orally aripiprazole and control group did olanzapine for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2nd , 4th , 6th and 8th week. Results After treatment the total and each factor scores of the PANSS in both groups low- ered more significantly compared with pretreatment （P〈0.01）, at the end of the 8th week there were no significant differences in obvious effective and effective rate between research and control group （66.7% vs 70.0%, 83.3% vs86.7%, χ2= 0.08, 0.13, P〉0.05）. The incidence of adverse reaction was significant- ly lower in research than in control group （33.3%vs 63.3%, χ2=5.41,P〈0.05）. Conclusion Aripi- prazole could effectively improve various kinds of mental symptoms, its efficacy is equivalent to olanzap- ine, its adverse reactions are mild, and it has little influence on body mass, higher safety and better com- pliance in first-episode schizophrenia.